| systematic review | Q1504425 |
| scholarly article | Q13442814 |
| P50 | author | Suresh Senan | Q37830477 |
| Berend J Slotman | Q40690934 | ||
| P2093 | author name string | Cornelis J A Haasbeek | |
| Sashendra Senthi | |||
| P2860 | cites work | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860606 |
| P2507 | corrigendum / erratum | Corrigendum to “Outcomes of stereotactic ablative radiotherapy for central lung tumours: A systematic review” [Radiother Oncol 106 (2013) 276–282] | Q59587377 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adaptive radiation therapy | Q180507 |
| systematic review | Q1504425 | ||
| P304 | page(s) | 276-282 | |
| P577 | publication date | 2013-02-22 | |
| P1433 | published in | Radiotherapy and Oncology | Q14251029 |
| P1476 | title | Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review | |
| P478 | volume | 106 |
| Q41635905 | A Retrospective Analysis of Toxicity and Efficacy for 2 Hypofractionated Irradiation Schedules Versus a Conventional One for Post-Mastectomy Adjuvant Radiotherapy in Breast Cancer |
| Q28079625 | A critical review of recent developments in radiotherapy for non-small cell lung cancer |
| Q47877896 | A phase I/II study on stereotactic body radiotherapy with real-time tumor tracking using CyberKnife based on the Monte Carlo algorithm for lung tumors |
| Q38790915 | A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer |
| Q29248448 | A treatment-planning comparison of three beam arrangement strategies for stereotactic body radiation therapy for centrally located lung tumors using volumetric-modulated arc therapy |
| Q57498590 | Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up |
| Q64325572 | Advances in proton therapy in lung cancer |
| Q92463820 | Antibiotic instillation for a chronic lung abscess |
| Q91910242 | Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial |
| Q51621075 | British Thoracic Society guidelines for the investigation and management of pulmonary nodules. |
| Q90144940 | Can thoracic nodes oligometastases be safely treated with image guided hypofractionated radiation therapy? |
| Q28083924 | Challenges in the treatment of early non-small cell lung cancer: what is the standard, what are the challenges and what is the future for radiotherapy? |
| Q38663392 | Clinical Outcomes of 130 Patients with Primary and Secondary Lung Tumors treated with Cyberknife Robotic Stereotactic Body Radiotherapy |
| Q53527650 | Comparison of Effects Between Central and Peripheral Stage I Lung Cancer Using Image-Guided Stereotactic Body Radiotherapy via Helical Tomotherapy. |
| Q91323191 | Comparison of single- and five-fraction schedules of stereotactic body radiation therapy for central lung tumours: a single institution experience |
| Q60961749 | Complete remission after hypofractionated radiotherapy for a patient with inoperable adenoid cystic carcinoma of bronchus: A case report |
| Q43191730 | Cons: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy? |
| Q89869712 | Contrast enhanced oesophageal avoidance for stereotactic body radiotherapy: Barium vs. Gastrografin |
| Q53083823 | DART-bid: dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily: high local control in early stage (I/II) non-small-cell lung cancer. |
| Q37468265 | Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer |
| Q99582784 | Dose-response relationship of stereotactic body radiotherapy for ultracentral tumor and comparison of efficacy with central tumor: a meta-analysis |
| Q34623353 | Dosimetric predictors of esophageal toxicity after stereotactic body radiotherapy for central lung tumors |
| Q45794075 | Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. |
| Q38641099 | Emerging Role of MRI for Radiation Treatment Planning in Lung Cancer |
| Q39089325 | Emerging radiotherapy technology in a developing country: A single Brazilian institution assessment of stereotactic body radiotherapy application |
| Q37151785 | Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree |
| Q36840379 | Hypofractionated radiotherapy for medically inoperable stage I non-small cell lung cancer |
| Q38274876 | Interventional oncology in multidisciplinary cancer treatment in the 21(st) century. |
| Q43756128 | Investigating strategies to reduce toxicity in stereotactic ablative radiotherapy for central lung tumors |
| Q64997326 | Lobectomy versus stereotactic ablative radiotherapy for medically operable patients with stage IA non-small cell lung cancer: A virtual randomized phase III trial stratified by age. |
| Q34771688 | Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy |
| Q38261944 | Lung cancer. Radiotherapy in lung cancer: Actual methods and future trends |
| Q41710571 | Lung metastases in oligometastatic patients: outcome with stereotactic body radiation therapy (SBRT). |
| Q36235727 | LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective |
| Q36485777 | Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours - a clinical physics perspective |
| Q92545461 | MR-guidance in clinical reality: current treatment challenges and future perspectives |
| Q53061916 | Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. |
| Q34005116 | Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada |
| Q92891968 | Moderately Hypofractionated Radiotherapy Alone for Stage I-IIB Non-small Cell Lung Cancer |
| Q38220335 | Novel treatment options in stage I non-small-cell lung cancer |
| Q89924278 | Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors |
| Q96305367 | Outpatient Anesthesia Facilitates Stereotactic Body Radiation Therapy for Early Stage Lung Cancer Patients With Advanced Cognitive Impairments |
| Q64277127 | Phase II study of compensator-based non-coplanar intensity-modulated radiotherapy for Stage I non-small-cell lung cancer |
| Q36241814 | Pros: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy? |
| Q33638795 | Quantification of proton dose calculation accuracy in the lung |
| Q92040126 | Questionnaire survey on treatment planning techniques for lung stereotactic body radiotherapy in Japan |
| Q27022685 | Radiotherapy and the tumor stroma: the importance of dose and fractionation |
| Q38155854 | Recent advances in radiotherapy for thoracic tumours |
| Q26821815 | Regulation of miRNAs affects radiobiological response of lung cancer stem cells |
| Q92973685 | Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer |
| Q38813253 | SABR vs. Limited Resection for Non-small Cell Lung Cancer: Are We Closer to an Answer? |
| Q35200592 | SBRT in operable early stage lung cancer patients. |
| Q33786992 | Safety and efficacy of intensity-modulated stereotactic body radiotherapy using helical tomotherapy for lung cancer and lung metastasis |
| Q30317717 | Simultaneous stereotactic body radiation therapy of a primary non-small cell lung cancer and synchronous carcinoma in situ in a medically inoperable patient: case report |
| Q64956876 | Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial. |
| Q97537795 | Stereotactic ablative radiotherapy for malignant mediastinal and hilar lymphadenopathy: a systematic review |
| Q36169921 | Stereotactic ablative radiotherapy with CyberKnife for advanced thymic carcinoma: a case report |
| Q57177641 | Stereotactic body radiation therapy for lung, spine and oligometastatic disease: current evidence and future directions |
| Q60912983 | Stereotactic body radiation therapy for non-small cell lung cancer: A review |
| Q42554826 | Stereotactic body radiotherapy for central lung tumours |
| Q53054421 | Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis. |
| Q90017826 | Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: Initial outcomes |
| Q38374340 | Stereotactic body radiotherapy in operable patients with stage I NSCLC: where is the evidence? |
| Q36235528 | Stereotactic body radiotherapy with helical TomoTherapy for medically inoperable early stage primary and second-primary non-small-cell lung neoplasm: 1-year outcome and toxicity analysis |
| Q37109702 | Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes |
| Q28085744 | Stereotactic radiotherapy for early lung cancer: Evidence-based approach and future directions |
| Q43798893 | Surgery versus SABR for NSCLC. |
| Q48369218 | Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review. |
| Q33823049 | Survey of stereotactic ablative body radiotherapy in the UK by the QA group on behalf of the UK SABR Consortium |
| Q90175125 | The evolving role of radiotherapy in non-small cell lung cancer |
| Q92807807 | The irregular breathing effect on target volume and coverage for lung stereotactic body radiotherapy |
| Q64111832 | Three discipline collaborative radiation therapy (3 DCRT ) special debate: I would treat all early‐stage NSCLC patients with SBRT |
| Q38709677 | Ursolic acid sensitizes radioresistant NSCLC cells expressing HIF-1α through reducing endogenous GSH and inhibiting HIF-1α. |
| Q55441971 | [Stereotactic Body Radiotherapy for Centrally Located Non-small Cell Lung Cancer]. |
| Q59587377 | Corrigendum to “Outcomes of stereotactic ablative radiotherapy for central lung tumours: A systematic review” [Radiother Oncol 106 (2013) 276–282] | main subject | P921 |
Search more.